课题基金 / 基金详情

Melanoma Chemoprevention by Targeting Mutant (V600E) B-Raf

Melanoma Chemoprevention by Targeting Mutant (V600E) B-Raf
通过针对突变体 (V600E) B-Raf 进行黑色素瘤化学预防
批准号:
7215026
负责人:
Gavin P. Robertson
金额:
$7.21万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-09-22 至 2008-07-31

项目摘要

项目成果

Gavin P. Robertson的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):恶性黑色素瘤是所有皮肤癌中最致命的。一种名为B-Raf的蛋白质在大约90%的痣和癌前早期黑色素瘤细胞中突变为组成活性形式(V600E-B-Raf)。可以制备特异性降低突变型V600E-B-Raf蛋白表达的SiRNA,但不能降低正常野生型蛋白的表达。使用这种siRNA靶向V600E-B-Raf抑制黑色素瘤的早期发展,使其成为理想的化学预防剂。挑战在于开发一种策略,将这种针对V600E-B-Raf的化学预防性siRNA输送到皮肤细胞中,这也是该项目的目标。目前,没有技术或方法利用siRNA作为化学预防剂来抑制黑色素瘤的早期发展。本研究的核心化学预防假设是,通过新型超声脂质体技术将针对突变体V600E-B-Raf的siRNA递送到含有早期黑素细胞病变的皮肤中,将是一种有效的化学预防剂,可逆转或延缓痣或早期病变的发展。我们根据一个模型的初步发现提出了这一假设,在这个模型中,皮肤是在一个组织培养皿中制成的,培养皿中含有来自早期黑色素瘤的细胞,这些细胞在组织学上发展成类似于早期恶性前黑色素瘤的肿瘤。作为原理证明,我们可以证明siRNA对抗突变体V600E-B-Raf可以延缓这些早期黑色素细胞病变的发展。此外,我们正在开发一种新颖的创新技术,将皮肤超声与脂质体递送载体结合起来,将siRNA递送到皮肤中的癌细胞中。我们已经确定突变体V600E-B-Raf作为潜在的化学预防靶点,准备进行拟议的研究。此外,我们对含有早期黑素瘤的皮肤重建进行了初步数据处理,并将其暴露于装载siRNA的脂质体中,显示了该技术的潜在效用。此外,我们还组建了一个研究团队,该团队独特地结合了黑色素瘤、皮肤重建、siRNA靶向、超声波和脂质体技术等多学科专家,他们都对黑色素瘤和化学预防药物的开发有着长期的研究兴趣。这种化学预防剂的开发将通过减少黑色素瘤的发展显著影响人类健康,从而直接降低死亡率。
英文摘要
DESCRIPTION (provided by applicant): Malignant melanoma is the most deadly of all skin cancers. A protein called B-Raf is mutated to a constitutively active form (V600E-B-Raf) in approximately 90% of moles and premalignant early melanoma cells. SiRNA can be made that specifically reduces expression of mutant V600E-B-Raf protein but not normal wild-type protein. Targeting V600E-B-Raf using this siRNA inhibits early melanoma development making it an ideal chemopreventive agent. The challenge is to develop a strategy to deliver this chemopreventive siRNA against V600E-B-Raf into cells in the skin, which is the goal of this project. Currently, no technology or approach utilizes siRNA as a chemopreventive agent to inhibit early melanoma development. The central chemoprevention hypothesis for the proposed research is that siRNA against mutant V600E-B-Raf delivered via novel ultrasound-liposome technology into skin containing early melanocytic lesions will be an effective chemopreventive agent for reversing or retarding development of moles or early lesions. We formulated this hypothesis based on preliminary findings using a model in which skin is made in a tissue culture dish that contains cells derived from early-stage melanomas, which develop into tumors histologically resembling early premalignant melanomas. As proof-of-principle, we can show that siRNA against mutant V600E-B-Raf retards development of these early melanocytic lesions. Furthermore, we are developing a novel and innovative technology for delivering siRNA into cancer cells in skin that combines skin ultrasonication together with liposomal delivery vehicles. We are prepared to undertake the proposed research, having identified mutant V600E-B-Raf as a potential chemopreventive target. Furthermore, we have preliminary data using skin reconstructs containing early melanomas, which have been ultrasonicated and exposed to liposomes loaded with siRNA showing the potential utility of this technology. In addition, we have assembled a research team that uniquely combines multidisciplinary experts in melanoma, skin reconstruction, siRNA targeting, as well as ultrasound and liposome technology, each of who has long-standing research interests in melanoma and development of chemopreventive agents. Development of this chemopreventive agent would significantly impact human health by reducing melanoma development, thereby directly decreasing mortality rates.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting Aldehyde Dehydrogenase for Cancer Prevention
NMR IMAGING OF IRON OXIDE NANOPARTICLES
  • 批准号:
    8363206
  • 项目类别:
  • 资助金额:
    $0.31万
  • 财政年份:
    2011
  • 负责人:
    Gavin P. Robertson
  • 依托单位:
Synergistically Acting Targeted Therapeutics for Melanoma
Targeted Chemoprevention for Melanoma
国内基金
海外基金
Hm2E8-NCTD-liposomes靶向调节HLF/SLUG轴机制的研究
  • 批准号:
    81200386
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    23.0万元
  • 批准年份:
    2012
  • 负责人:
    张晶樱
  • 依托单位: